Advanced search×

Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

Luigi L Mazzone, Laura L Reale, Valeria V Mannino, Mariadonatella M Cocuzza, and Benedetto B Vitiello

CNS Drugs 25(6):503-9 (2011) PMID 21649450

Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine.

DOI: 10.2165/11590450-000000000-00000
Version: za2963e q8zac q8zb3 q8zc4 q8zdc q8zec q8zf9 q8zg0

Similar articles you may find interesting…

  1. Review: childhood ADHD increases the risk of nicotine use in adolescence and alcohol use in young adulthood.
    Steve S Lee

    Evid Based Ment Health (2011) PMID 21571756

  2. [Stimulant and non-stimulant medication in current and future therapy for ADHD].
    A G AG Franke, A A Konrad, ... M M Huss

    Fortschr Neurol Psychiatr 80(3):130-40 (2012) PMID 21611939

    The current pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) is mainly based on the stimulant methylphenidate and to a small extent on amphetamines which are not approved in Germany. The only approved non-stimulant so far is atomoxetin (Strattera®), a norepinephri...